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Abstract
Background Sarcopenia is rarely diagnosed and is not recorded electronically in routine clinical care, posing
challenges to trial recruitment. We describe the performance of four components of a strategy to efficiently recruit
participants with sarcopenia to a trial of perindopril and/or leucine for sarcopenia: primary care vs. hospital recruit-
ment, a comparison of central vs. local telephone pre-screening, performance of a questionnaire on physical function
conducted as part of the pre-screening telephone call, and performance of bioimpedance measurement to identify
low muscle mass.
Methods Hospital-based recruitment took place through inpatient and outpatient geriatric medicine services. Local
research nurses reviewed medical notes and approached potentially eligible patients. Primary care recruitment
reviewed primary care lists from collaborating practices, sending mailshots to patients aged 70 and over who were
not taking angiotensin-converting enzyme inhibitors. Telephone pre-screening was conducted either by research
nurses at each site or centrally by Tayside Clinical Trials Unit. The 10-point SARC-F questionnaire was used for pre-
screening. De-identified recruitment information was held on a central electronic tracking system and analysed using
SPSS. Bioimpedance was measured using the Akern BIA 101 system, with the Sergi equation used to estimate lean
mass.
Results Fourteen UK sites recruited to the trial. The 1202 sets of notes in hospital-based care were reviewed at these
sites; 7 participants (0.6% of total notes screened) were randomized. From primary care, 13 808 invitations were sent;
138 (1.0% of total invited) were randomized. 633/2987 primary care respondents were pre-screened centrally; the
mean number of calls per respondent was 2.3. For 10 sites where central and local pre-screening could be compared,
the conversion rate from pre-screening to randomization was 18/588 (3.1%) for centralized calls, compared with
73/1814 (4.0%) for local pre-screening calls (P = 0.29). A weak relationship was seen between higher (worse)
SARC-F score at screening and lower likelihood of progression to randomization (r = 0.08, P = 0.03). Muscle
mass estimates generated using the Sergi equation were systematically biased, and a recalibrated equation for
bioimpedance-estimated muscle mass was derived.
Conclusions Primary care recruitment led to higher response rates and overall numbers randomized than
hospital-based recruitment. Centralized pre-screening saved local research nurses’ time but did not improve conver-
sion to randomization. SARC-F did not help to target screening activity in this sarcopenia trial, and a recalibration
of the equation for estimating muscle mass from bioimpedance measures may improve accuracy of the screening
process.
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Introduction
Sarcopenia is the loss of muscle strength and mass that
commonly accompanies advancing age.1 It is a major health
issue thought to affect millions of older people, with a prev-
alence of between 5% and 10% in those aged 65 and over
in the UK according to the 2010 European Working Group
on Sarcopenia (EWGSOP) criteria.2 Sarcopenia is associated
with incident disability, falls, hospital admission and longer
length of stay, and earlier death.3–5 The cost of sarcopenia
in the UK has been estimated at 2 billion pounds per annum.6
Existing evidence supports resistance exercise training as an
effective intervention,7 but not all older people are willing
or able to undertake such training. New therapies, both phar-
macological and non-pharmacological, are therefore needed
to treat and prevent this condition.8
Sarcopenia is a relatively newly described condition, and as
such, it presents a number of challenges when attempting to
conduct randomized controlled trials. A diagnosis of
confirmed sarcopenia requires both measurement of muscle
strength and muscle mass,1 neither of which are routinely col-
lected in clinical practice. Until recently, no International Clas-
sification of Diseases-10 code was available for sarcopenia,9
and the diagnosis is still not routinely made10 or recorded in
either paper or electronic clinical records. Although older
people are familiar with the concept of muscle weakness,
few will have heard of the term sarcopenia, and fewer still will
recognize that the diagnosis applies to them. Finding and
recruiting participants to trials for sarcopenia is therefore
more challenging than for conditions with well-established
public awareness, diagnostic pathways, and coding systems.
In order to better understand how to find and recruit the
target populations for sarcopenia trials, studies are required
that evaluate different channels of recruitment, different
screening methods, and different ways to efficiently evaluate
both muscle strength and muscle mass as part of the screen-
ing process. The aim of the work reported later was therefore
to better understand how to efficiently recruit participants to
future trials of sarcopenia therapies, using data from the
multicentre Leucine and Angiotensin Converting Enzyme in-
hibitors for sarcopenia (LACE) randomized controlled
sarcopenia trial.11 We assessed the performance of four
components of our screening pathway: (a) primary care vs.
hospital-based care recruitment methods; (b) central vs. local
telephone pre-screening; (c) use of a simple telephone phys-
ical function questionnaire as part of pre-screening; and (d)
ability of bioimpedance measurement to identify those with
low muscle mass at the screening visit. We also evaluated
whether the recruitment pathway was successful in
recruiting a trial population fulfilling the definition of
sarcopenia from different guidelines.
Methods
Trial description
The LACE trial was a multicentre, parallel-group, 2 × 2 facto-
rial, double-blind, placebo controlled, randomized trial test-
ing the effect of perindopril and/or leucine in older people
with sarcopenia. LACE sought to enrol patients aged 70 and
over with sarcopenia, defined as a low muscle mass and
low muscle strength (either low grip strength or low gait
speed). Exclusion criteria included the current use of, or
contraindications to, angiotensin-converting enzyme (ACE)
inhibitors or angiotensin receptor blockers, heart failure,
severe chronic obstructive pulmonary disease, other skeletal
myopathies, or advanced chronic kidney disease. Participants
received perindopril or placebo starting at 2 mg and titrated
up to 4 mg once daily after 2 weeks, if tolerated. Participants
also received 2.5 g three times a day of leucine or placebo
powder with food. All interventions were given for
12 months. The primary outcome for the trial was the
between-group difference in the Short Physical Performance
Battery12 measured over the course of the trial; secondary
endpoints included muscle mass measured by dual X-ray
absorptiometry (DXA) scanning, handgrip strength, quadri-
ceps strength, 6 min walk distance, activities of daily living
measured by the Nottingham Extended Activities of Daily
Living Scale,13 quality of life measured with the EQ 5D-3L
tool, and falls measured by monthly falls diaries. Blood
samples were taken for safety monitoring and studies into
biomarkers and mechanisms. The full protocol has been pub-
lished previously.11 The trial was funded by the NIHR/MRC
Efficacy and Mechanisms Evaluation funding stream (grant
13/53/03). The trial was registered online (www.isrctn.com;
ISRCTN90094835). Approval for the study was given by the
East of Scotland Research Ethics Committee (reference 14/
ES/1099), and by the UK Medicines and Healthcare products
Regulatory Agency (EudraCT number 2014-003455-61); the
trial was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki and
its later amendments. The sponsor was Tayside Academic
Sciences Centre.
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Recruitment
The recruitment strategy for the LACE trial used several
components. Groups likely to contain a higher than average
proportion of people with sarcopenia were identified from
primary care or hospital-based care geriatric medicine
services. Next, telephone pre-screening was used to exclude
those less likely to have sarcopenia, and then finally,
in-person screening was conducted to test muscle strength
and estimate muscle mass. Recruitment took place at 14 sites
across the UK. The recruitment pathway for the LACE trial is
show in Figure 1 along with the aspects of the pathways
assessed in this analysis.
For primary care recruitment, GP practices within easy
reach of an hospital-based care centre were approached.
Those who agreed to collaborate with participant
Figure 1 Flowchart of recruitment in the Leucine and Angiotensin Converting Enzyme inhibitors for sarcopenia (LACE) trial and four components
(in green) of screening pathway assessed. DXA, dual X-ray absorptiometry.
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identification reviewed their practice lists to identify patients
aged 70 and over; not taking ACE inhibitors; and without
heart failure, chronic obstructive pulmonary disease, aortic
stenosis, chronic kidney disease Stages 4 or 5, or thyrotoxico-
sis. Potentially eligible participants were sent a brief (two
pages) information sheet with reply slip and paid-for return
envelope. Participants who returned the reply slip indicating
interest in the trial were then contacted by telephone for pre-
screening. Pre-screening telephone calls were conducted by
local research nurses for some centres, but for centres lacking
the staff capacity to do this, telephone pre-screening was
conducted centrally by non-clinical staff in the Tayside
Clinical Trials Unit.
Hospital-based recruitment was conducted via inpatient
and outpatient geriatric medicine services at each site.
Local research nurses reviewed medical notes and then
approached potentially eligible patients face-to-face or via
letter if time was not available for an approach during clinic.
Pre-screening process
At pre-screening (performed by telephone for most partici-
pants, but face-to-face in clinic for some participants in hospi-
tal-based care), questions regarding potential exclusion
criteria were asked, along with the 10-point SARC-F
questionnaire.14 This questionnaire sums results from five
simple questions about everyday function and has been
proposed as a screening score to identify patients with
sarcopenia. The optimal cut-off for identifying patients with
sarcopenia in a UK population is not known. The protocol
therefore allowed the threshold score for the SARC-F to be
changed during the trial. At the start of the trial, a SARC-F
score of 4 or more was required to proceed from
pre-screening to a screening visit. This was adjusted after
6 months of recruitment to a threshold of three points to in-
crease the number of participants proceeding to a screening
visit. Participants passing the pre-screening process were
sent the full information sheet and then invited to attend a
face-to-face screening visit.
Screening visit
At the screening visit, muscle mass was measured using the
Akern 101 bioimpedance analyser (Akern, Italy). Initially, the
Janssen equation15 was used to derive whole-body lean mass
from the bioimpedance measures. After 6 months of recruit-
ment, a comprehensive review of the screening criteria was
undertaken in light of slow recruitment and very high
(>95%) rates of failed screening visits (20 screening visits
but only one participant randomized). After consideration
of new information about the accuracy and population spec-
ificity of different equations for estimating muscle mass by
bioimpedance, we changed to using the Sergi equation16 to
estimate appendicular lean mass. Values from bioimpedance
analysis (BIA) (reactance and resistance) are converted by the
Sergi equation to predict appendicular skeletal muscle mass
(ASMM) index (ASMM/height2). The Sergi equation was
derived from bioimpedance measures using the same BIA
system as used for screening in the LACE trial (the Akern
BIA 101), compared with DXA appendicular muscle mass; this
is in contrast to the Janssen equation that was calibrated
against whole-body skeletal muscle measurements from
magnetic resonance imaging scanning. The Sergi equation
was derived in an older, white, European (but non-UK) popu-
lation, and independent validation data are lacking on how
well the equation can predict DXA-measured muscle mass
and hence its utility as a screening tool in sarcopenia trials.
In addition, we reviewed muscle mass thresholds for trial in-
clusion, driven by high screen fail rates, particularly in those
with obesity and muscle weakness. We therefore moved
from a whole-body lean mass threshold stratified by sex
(<13 kg for women, <20.5 kg for men) to appendicular lean
mass thresholds stratified by sex and body mass index (BMI),
with cutpoints derived from data in the UK Biobank study17
(Supporting Information, Table S1). This change was made
to ensure representation of patients with both obesity and
sarcopenia, in line with new guidance from the USA.18
Muscle strength was measured using handgrip dynamom-
etry (the maximum value of two attempts on each hand
was taken). Gait speed was measured over a 4 m course. To
be eligible for entry to the trial, participants had to have
muscle mass below the sex and BMI-specific threshold, and
either a gait speed of <0.8 m/s or a maximum handgrip
strength below 20 kg (women) or below 30 kg (men).
Baseline visit
At the baseline visit, baseline data for the primary and
secondary outcomes were collected, including appendicular
muscle mass measured using whole-body DXA scanning.
Scanning was conducted using Hologic or Lunar DXA scan-
ners, using proprietary software. Each scanner was regularly
calibrated using a site-specific phantom, but cross-scanner
calibration was not performed. DXA for muscle mass has pre-
viously been shown to have good repeatability and strong
correlation with magnetic resonance imaging-measured
muscle mass.19
Data processing and analysis
De-identified recruitment information was held on a central
electronic tracking system designed and hosted by the
University of Dundee Health Informatics Centre. De-identified
screening visit and baseline trial visit data were entered by
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local research nurses onto OpenClinica (OpenClinica LLC,
Waltham, MA, USA); after data cleaning and verification by
the Tayside CTU team, screening and baseline data were
extracted as flat files without any indication of treatment
allocation. All analyses were performed using SPSS v24
(IBM, New York, USA). A two-sided P value of <0.05 was
taken as significant for all analyses. Descriptive data were
generated for all participants who attended a screening visit
and for all participants who underwent baseline visit mea-
surements including DXA scanning. Categorical variables
were compared using Pearson’s χ2 test. Correlations were
tested using Spearman’s rho.
Estimates of ASMM index derived via the Sergi equation at
the screening visit were compared with ASMM index mea-
sured by DXA at the baseline visit. Bland–Altman plots were
generated to compare the difference in estimated and
measured ASMM index across the measurement range.
Multivariable linear regression using forced entry of variables
was used to generate a new study-specific equation relating
bioimpedance outputs to DXA-measured ASMM, which was
then calibrated to the study population. Finally, as a test of
how successful the overall screening process was in identify-
ing the target group for the trial (i.e. those fulfilling the defini-
tion of sarcopenia), we calculated the proportion of patients
randomized who met the EWGSOP 2010 definition,20 which
formed the original basis for inclusion in LACE. Given recent
changes in consensus definitions of sarcopenia since the LACE
trial was planned, we also calculated the proportion who met
two other definitions—from the updated 2019 EWGSOP
guidelines,21 and the Foundation for the National Institutes
of Health consensus definition originating in the USA.18
Results
A total of 320 participants attended a screening visit and 145
participants were randomized into the trial between June
2016 and December 2018. Table 1 shows the characteristics
of those attending the screening visit and those who were
randomized. Of the 2897 individuals who underwent tele-
phone pre-screening, 1746 had a SARC-F score of <3 and
were thus ineligible; 241 had other reasons for ineligibility
(excessive weight loss, presence of a pacemaker or defibrilla-
tor, already taking ACE inhibitors, angiotensin receptor
blockers or other prohibited medications, undertaking phys-
iotherapy or unable to walk without human assistance), 255
declined to proceed after discussing the trial by telephone,
a further 217 declined to proceed after reading the full trial
information, and 118 did not proceed to screening due to
trial recruitment closing. Of the 320 attending a screening
visit, 129 did not proceed due to failure to meet the
screening criteria for sarcopenia.
Primary care vs. hospital-based screening
Figure 2 shows a comparison of flow through the primary
care and hospital-based screening pathways. The proportion
of participants randomized from those approached was not
significantly higher in primary care than in hospital-based
care (138/13808 (1.0%) vs. 7/1202 (0.6%); P = 0.16) but the
volume of participants able to be approached and random-
ized through the primary care pathway was much higher.
Table 1 Characteristics of participants attending screening visit and baseline visit for muscle mass measurement
Characteristic
Attended screening
visit (n = 320)
Randomized with
valid baseline DXA
data (n = 144)
Mean age (years) (SD) 77.7 (5.6) 78.8 (6.0)
Female sex (%) 190 (59) 78 (54)
Mean handgrip strength (kg) (SD) Men (n = 123) 24.8 (7.0) Men (n = 66) 23.1 (5.9)
Women (n = 151) 14.3 (4.4) Women (n = 78) 13.7 (3.9)
Mean BIA muscle massa (kg/m2) (SD) Men (n = 130) 7.49 (1.37) Men (n = 66) 7.64 (1.34)
Women (n = 188) 5.79 (1.82) Women (n = 78) 5.17 (1.17)
Mean SPPB (SD) (n = 282) 6.8 (2.7) 7.0 (2.3)
Mean gait speed (m/s) (SD) (n = 271) 0.76 (0.25) 0.75 (0.23)
Median chair stand time (s) [IQR] 21 [16–28] 22 [17–28]
Proportion (%) with low grip strength (<30 kg M, <20 kg F) 231/274 (84) 135/144 (94)
Proportion (%) with low grip strength (<27 kg M, <16 kg F) 174/274 (64) 104/144 (72)
Proportion (%) with low muscle mass index
(BIA) (<7.26 kg/m2 M, <5.45 kg/m2 F)
143/318 (45) 73/144 (51)
Low BIA muscle mass on BMI stratum (%) <18.5 kg/m2 7/7 (100) 4/4 (100)
18.5–24.9 kg/m2 68/81 (84) 29/34 (85)
25.0–29.9 kg/m2 100/132 (76) 58/74 (78)
≥30 kg/m2 49/98 (50) 18/32 (56)
Total 224/318 (70) 109/144 (76)
BIA, bioimpedance analysis; BMI, body mass index; DXA, dual X-ray absorptiometry; IQR, interquartile range; SPPB: Short Physical Perfor-
mance Battery.
aASMM/height2 estimated using Sergi equation.
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Centralized pre-screening telephone calls
A total of 633/2897 primary care respondents were pre-
screened centrally; the mean number of calls per respondent
was 2.3. More than one attempt was required to make con-
tact with some respondents as telephone calls went unan-
swered. At 10 sites, pre-screening was conducted partly by
the local study team and partly by central pre-screening to
augment the capacity of the local study team to respond to
expressions of interest in the study in a timely manner. At
these 10 sites, the conversion rate from pre-screening to ran-
domization was 18/588 (3.1%) for centralized calls, compared
with 73/1814 (4.0%) for local pre-screening calls (P = 0.29).
SARC-F performance as a pre-screening tool
A weak relationship was seen between higher (worse) SARC-F
score at pre-screening and lower likelihood of progression to
randomization (r = 0.08, P = 0.03); the association was
stronger in men (r = 0.13, P = 0.04) than in women
(r = 0.05, P = 0.29). Details of conversion rates by SARC-F
score are given in Figure 3, and a breakdown by sex is shown
in Figure S1A and S1B. Participants with a SARC-F score of
less than 3 did not progress to screening; thus, we were un-
able to assess the relationship between SARC-F scores of 0
to 2 and likelihood of progression to randomization.
The SARC-F score at pre-screening showed a modest asso-
ciation with handgrip strength for both men (r = 0.29,
P < 0.001) and women (r = 0.17, P = 0.03). A similar corre-
lation (r = 0.28, P < 0.001) was seen between SARC-F score
and 4 m gait speed at screening. A significant correlation was
found between SARC-F and ASMM index measured by
bioimpedance for men (r = 0.19, P = 0.04) but not for
women (r = 0.05, P = 0.47). Figure S2A to S2D shows the re-
lationship between SARC-F score at pre-screening and the
proportion of participants with low grip strength, low gait
speed, and low muscle mass measured by bioimpedance.
Even with a SARC-F score of 3, the majority of participants
had low muscle strength (as defined by the 2010 and the
Figure 2 Primary care vs. hospital-based care screening yield.
Figure 3 Conversion rate to screening visits and randomization by
SARC-F score at pre-screening.
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2019 EWGSOP thresholds); the proportion with low muscle
mass was little different in those with a SARC-F score of 3
or 4 than for those with higher SARC-F scores.
Performance of bioimpedance analysis as a
screening test for low muscle mass on dual X-ray
absorptiometry
A total of 144 participants underwent DXA at the baseline
visit and had usable data. Baseline details are shown for these
144 participants in Table 1. Figure S3 shows the correlation
(r = 0.79, P < 0.001) between DXA-measured baseline ASMM
index and ASMM index estimated via the Sergi equation from
screening BIA data. Figure 4 shows the Bland–Altman plot
comparing estimated and measured ASMM index; while over-
all agreement was good, with BIA underestimating ASMM in-
dex by only 0.17 kg (SD 1.11), estimates were systematically
biased, with greater underestimation of ASMM index at lower
ASMM index, and overestimation at higher ASMM indices.
The overall bias amounted to 0.5 kg of underestimation for
every 1 kg lower ASMM index.
An alternative equation was derived to fit data from the
LACE trial, using the results of a linear regression analysis
(shown in Table S2) with further adjustment to calibrate the
new equation with the observed DXA results. The final
equation to predict ASMM index as measured by DXA from
bioimpedance was:
1:15 ð10:251  Age in years 0:011½ 
þ Sex ¼ 1 for male;0 for female½ 
 Rz 0:003½  þ Xc 0:011½ 
 Height in cm 0:031½ 
þ Weight in kg 0:044½ Þ  1:275
Rz, resistance. Xc, reactance.
Figure S4 shows that Bland–Altman plot comparing this
cohort-specific estimate with the measured DXA appendicu-
lar skeletal muscle mass index; the mean difference between
estimated and measured appendicular skeletal muscle
mass index was 0 (SD 0.5) kg/m2, and no systematic bias
was evident.
Proportion of randomized participants meeting
different definitions of sarcopenia
Table 2 shows the percentage of randomized participants in
the LACE trial with DXA-measured baseline muscle mass that
met four different definitions of sarcopenia. The proportion
of included women with sarcopenia was lower than the pro-
portion for men for all definitions. Only one-third of included
participants met the original 2010 EWGSOP definition, but
the number meeting a definition of ‘probable sarcopenia’
Figure 4 Bland–Altman plot for agreement between appendicular skeletal muscle mass estimated by bioimpedance (Sergi equation) and measured by
DXA at baseline (n = 144). ASMMI, appendicular skeletal muscle mass index; BIA, bioimpedance analysis; DXA, dual X-ray absorptiometry. Graph shows
fit line with 95% confidence interval, together with mean difference and 95% confidence interval for difference.
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based on low grip under the revised (2019) EWGSOP guide-
lines was nearly three quarters of the total.
Discussion
We found that recruitment via primary care delivered many
more participants with sarcopenia than recruitment via
hospital-based care, a result of the much higher volume of
potential participants that could be reached, rather than a
large difference in the proportion of those screened who
were eligible to participate. Conducting pre-screening tele-
phone calls using a central team rather than the local site
teams performing telephone pre-screening did not lead to a
higher rate of conversion to in-person screening visits. The
SARC-F tool had limited utility in differentiating those at
pre-screening who would progress to randomization. Our
results suggest that using BIA and the Sergi equation as a
screening tool for low muscle mass is subject to systematic
bias in this group of older UK participants, underestimating
muscle mass in those with low muscle mass. This is likely to
lead to inclusion of participants who do not fulfil the muscle
mass criteria for sarcopenia on a more accurate measure
such as DXA scanning.
Previous studies have also found recruitment of partici-
pants meeting stringent definitions of sarcopenia (based on
low muscle strength and low muscle mass) to be difficult.
The PROVIDE trial22 recruited 380 participants and used a
two-category definition of sarcopenia based on the ratio of
skeletal muscle mass (measured by bioimpedance) to body
weight, thus avoiding the need for muscle mass to be below
an absolute threshold; only 70% of participants had a hand-
grip strength below the 2010 EWGSOP thresholds20 (<30 kg
for men and <20 kg for women).
Strengths of our analysis include our ability to examine
multiple components of the screening process. As such, we
were able to examine a range of different screening
techniques to evaluate which ones appeared successful. A
number of limitations also deserve comment. We did not
perform randomization to allocate different screening
techniques, either at an individual level or at a site level.
Conducting such randomized Studies Within a Trial (SWATs)
would have reduced bias and enabled more robust evidence
to be generated. However, not all processes within the
recruitment process would be amenable to randomization,
and additional embedded process evaluations (including
evaluations using qualitative methods) would have provided
valuable additional contextual information,23 for instance on
how participants made the decision to take part, and on
how study teams framed their conversations with potential
participants. Such information would be particularly valuable
given the significant number of otherwise eligible partici-
pants who chose not to attend a screening visit having
read the study information or discussed the study during
telephone pre-screening. We excluded participants with a
SARC-F score of less than 3 at pre-screening and so are un-
able to comment on the performance of the SARC-F score
at these levels; recent data suggest that using a very low
SARC-F cut-off (≥1 point) would enable a better balance be-
tween sensitivity and specificity for detecting those with
probable sarcopenia,24 thus increasing the number of poten-
tially eligible participants progressing from a pre-screening
telephone call to a screening visit, while still enabling exclu-
sion of those unlikely to have sarcopenia.
When we designed the LACE trial, the 2010 EWGSOP
criteria20 for sarcopenia were in use. Guidelines have changed
since then, making any comparison of screening tools with
these guidelines out of date. We have however also
endeavoured to assess our findings against currently used
criteria including the updated 2019 EWGSOP guidelines.21 In
terms of our assessment of muscle mass, we did not assess
BIA and DXA on the same day, which may have led to addi-
tional variability in measurements, as BIA is sensitive to
changes in fluid status. Our BIA measures, and the equation
we derived from our data, apply only to measures obtained
using the Akern BIA 101 system; other BIA systems require
their own calibration. Although we were able to derive an
equation that more accurately related muscle mass estimated
by BIA to that measured by DXA in our study population, this
Table 2 Proportion of randomized participants meeting different sarcopenia criteria
EWGSOP 2010a EWGSOP 2019 low gripb
EWGSOP 2019 confirmed
sarcopeniac FNIHd
Men (%) 30/66 (45) 50/66 (76) 15/66 (23) 27/66 (41)
Women (%) 24/78 (31) 54/78 (69) 17/78 (22) 22/78 (28)
All (%) 54/144 (38) 104/144 (72) 32/144 (22) 49/144 (34)
EWGSOP, European Working Group on Sarcopenia; FNIH, Foundation for the National Institutes of Health.
aLow grip strength (<30 kg men or <20 kg women) OR gait speed <0.8 m/s, AND low appendicular muscle mass index (<7.26 kg/m2 men
or <5.45 kg/m2 women).
bLow grip strength (<27 kg men or <16 kg women).
cLow grip strength (<27 kg men or <16 kg women) AND low appendicular muscle mass index (<7.0 kg/m2 men or <5.5 kg/m2 women).
dLow grip strength (<26 kg men or <16 kg women) AND low appendicular lean mass (lean mass in kg divided by body mass index in
kg/m2 < 0.789 for men or <0.512 for women).
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equation is likely to be overfitted for this study population and
requires validating in different samples, albeit those recruited
from a population of similar age and composition.15,25
What do these results mean for how we should design
recruitment pathways for sarcopenia trials? First, recruit-
ment through primary care provides an efficient, if
low-yield strategy; many thousands of potential participants
can be reached by mailshot at low cost. Searching elec-
tronic healthcare databases as part of such a strategy also
enables identification of those with common exclusion
criteria (such as the use of ACE inhibitors in the LACE trial)
at an early stage in the screening process. However, the
use of pre-screening questionnaires such as SARC-F to iden-
tify those more likely to have sarcopenia appears to add lit-
tle to the screening process. Pre-screening could be
confined to questions about other inclusion and exclusion
criteria not addressable in electronic searches, although it
is still possible that a lower threshold for the SARC-F would
still have utility in excluding those who are unlikely to have
sarcopenia. Central pre-screening can support delivery of a
high-volume pre-screening strategy but in our study ap-
peared to offer no clear advantage to local pre-screening
in terms of the conversion rate from pre-screening to ran-
domization. It is possible that central pre-screening by staff
who are clinically trained might be more effective, both in
terms of being able to answer questions from potential
participants but also in establishing the confidence of po-
tential participants; further study of this issue is required.
However, central pre-screening, even by clinically trained
staff, does not enable the local study team to start building
a relationship with potential participants, which might af-
fect trial retention. It is noteworthy that one-sixth of partic-
ipants at telephone pre-screening chose not to proceed
despite being eligible, highlighting this call as a decision
point in need of further study. Local pre-screening tele-
phone calls should therefore be preferred if the volume
of calls can be handled by the local team.
The revised EWGSOP guidelines for sarcopenia may enable
a change of focus in how we identify and recruit participants
for sarcopenia trials. The guidelines now enable a diagnosis of
probable sarcopenia to be made solely on the presence of
low handgrip strength; low muscle mass is required only as
a confirmatory measurement. This change acknowledges that
the practical difficulties in measuring muscle mass in clinical
practice,26 and also takes into account that muscle strength
rather than size, are the more important factors determining
physical function and prognosis.27 Designing sarcopenia trials
to target and enrol those with probable sarcopenia would
dispense with the need to screen for low muscle mass before
entry and would align research practice with what is feasible
and prevalent in clinical practice—grip strength is being mea-
sured more widely in geriatric medicine and rehabilitation
services now, but muscle mass is not. Targeting those with
probable sarcopenia, with the introduction of handgrip
strength testing as a routine measure in clinical services,
would also enable successful screening and recruitment from
hospital-based settings.
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